How Does DexCom Company Work and What Drives Its Business Model?

DexCom primarily sells CGM hardware and software: the G7 disposable sensor-transmitter integrated to smartphones and the emerging Stelo platform for broader clinical use. The stack includes sensors, transmitters (where applicable), mobile apps, and clinician-facing data tools that enable continuous glucose monitoring and analytics.

Customers – Type 1, insulin-intensive Type 2, and expanding non-insulin Type 2 users – buy CGM for better glycemic control: clinical trials and real-world studies tie CGM use to lower HbA1c and higher Time in Range, and to fewer severe hypoglycemic events, driving quality-of-life and reduced acute-care use.

CGM replaces intermittent fingerstick testing that misses fast glucose swings and nocturnal hypoglycemia; DexCom sensor technology provides five-minute updates and trend alerts so patients and clinicians can act before events occur. This addresses adherence gaps and the need for continuous, remote data for care teams.

Payers reimburse CGM because evidence shows lower hospitalization and complication costs; Medicare expanded coverage (2023 – 2025 policy rollouts) and private insurers grew uptake, supporting DexCom's recurring revenue model from sensors and app services. In fiscal 2025 DexCom reported total revenue of $4.60 billion, reflecting sustained demand for sensors and subscription-like repeat purchases.

Most revenue comes from high-frequency sensor replacements sold on prescription and through pharmacy fill programs; fiscal 2025 revenue exceeded 4.5 billion dollars, driven by recurring sensor volume.

DexCom has shifted pricing to favor broader volume, lowering per-unit ASPs while growing user penetration (including Type 2 non-insulin users via the Stelo brand) and expanding pharmacy and cash-pay channels.

Recurring sensor repurchases produce predictable cadence and stickiness; gross margins stayed in the 61 to 63 percent range in 2025, underpinning revenue quality.

Cash flow benefits from strong gross margins, scaling operating leverage as R&D and SG&A spread over a growing installed base, and rising direct-to-consumer cash-pay receipts diversifying reimbursement dependence.

Once patients adopt DexCom continuous glucose monitoring and integrate it with automated insulin delivery, switching costs rise – hardware compatibility, data histories, and clinician workflows create durable retention. FDA approvals and Medicare/insurance reimbursement further raise barriers to entry and sustain recurring revenue.

Proprietary sensor technology, real-world outcomes data, and partnerships with insulin pump companies and EHR vendors strengthen product stickiness. In 2025 DexCom reported expanding prescription share in the U.S. CGM market and growing uptake in Type 2 non-insulin patients, underpinning subscription and recurring revenue.

Abbott's FreeStyle Libre drives aggressive pricing and channel competition; margin compression risk is real given hardware and sensor price sensitivity. DexCom's revenue depends on reimbursement rates and payer policies, exposing it to policy shifts and procurement negotiations.

As of March 2026 the professional view is that DexCom remains a market leader with dominant U.S. CGM share and strong clinical adoption, but its premium valuation increasingly hinges on success expanding into the under-penetrated Type 2 non-insulin and health-sensing markets and defending margins against Abbott and payer pressure.